ЭФФЕКТИВНОСТЬ ИНГИБИТОРОВ КАЛЬЦИНЕВРИНА В ЛЕЧЕНИИ СТЕРОИДРЕЗИСТЕНТНОГО НЕФРОТИЧЕСКОГО СИНДРОМА У ДЕТЕЙ
Keywords:
стероидрезистентный нефротический синдром, ингибиторы кальциневрина, такролимусAbstract
Стероидрезистентный нефротический синдром (СРНС) у детей требует эскалации терапии за рамки глюкокортикоидов. Ингибиторы кальциневрина (ИКН) - циклоспорин А (ЦсА) и такролимус (ТАК) - являются основой терапии второй линии, однако сравнительные данные об их эффективности из Центральной Азии не опубликованы
Downloads
References
1. Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61–74. С. 61–66
2. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–1561. С. 1529–1561
3. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. С. 629–636
4. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–938. С. 931–935
5. Buscher AK, Beck BB, Melk A, et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11(2):245–253. С. 245–250
6. Tejani A, Butt K, Rajpoot D, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 1987;32(5):760–764. С. 760–763
7. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Eur J Pediatr. 1993;152(4):357–361. С. 357–360
8. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome. Am J Kidney Dis. 2009;53(5):760–769. С. 760–768
9. Li T, Wu HM, Wang F, et al. Tacrolimus versus cyclosporine for induction therapy of lupus nephritis. Cochrane Database Syst Rev. 2012;2012(3):CD008561. С. 1–30
10. Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 2012;82(10):1130–1135. С. 1130–1134
11. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. С. S155–S168 (Глава 6: СРНС)
12. Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017;91(4):937–947. С. 937–942
13. Sinha A, Bagga A, Banerjee S, et al. Steroid-sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2021;58(5):461–481. С. 461–475
14. Ranganathan S, Krishnamurthy S, Rajesh NG, et al. Randomized trial of tacrolimus versus cyclosporine in steroid-resistant nephrotic syndrome: the TOPHI trial. Pediatr Nephrol. 2021;36(4):907–916. С. 907–913
15. Basu B, Mahapatra TK, Mondal N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics. 2015;136(1):e132–e139. С. e132–e136
16. Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24(10):1689–1697. С. 1689–1695
17. Trautmann A, Schijvens AM, Lipska-Ziętkiewicz BS, et al. Long-term outcome in children with steroid-resistant nephrotic syndrome: a multicentre cohort study. Pediatr Nephrol. 2023;38(5):1473–1484. С. 1473–1480
